Assessing health status in inflammatory bowel disease using a novel single-item numeric rating scale

Digestive Diseases and Sciences

Volumn 58, Issue 5, 2013, Pages 1313-1321

  Surti, Bijal ^a,b   Spiegel, Brennan ^b,c,d   Ippoliti, Andrew ^a   Vasiliauskas, Eric A ^a   Simpson, Peter ^a   Shih, David Q ^a   Targan, Stephan R ^a   McGovern, Dermot P B ^a   Melmed, Gil Y ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Crohn's disease; Health related quality of life; Inflammatory bowel disease; Patient reported outcome; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HARVEY BRADSHAW INDEX; HEALTH STATUS; HUMAN; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; INTESTINE SURGERY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RELIABILITY; REMISSION; SIMPLE COLITIS CLINICAL ACTIVITY INDEX; SINGLE ITEM NUMERIC RATING SCALE; ULCERATIVE COLITIS; VALIDITY;

ADULT; AGED; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84878728460     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2500-1     Document Type: Article

References (51)

1. Magasi S, Ryan G, Revicki D, et al. Content validity of patient-reported outcome measures: perspectives from a PROMIS meeting. Qual Life Res. 2011;21:739-746.
2. Fiscella K, Ransom S, Jean-Pierre P, et al. Patient-reported outcome measures suitable to assessment of patient navigation. Cancer. 2011;117:3601-3615.
3. Marshall S, Haywood K, Fitzpatrick R. Impact of patient-reported outcome measures on routine practice: a structured review. J Eval Clin Pract. 2006;12:559-568.
4. Velikova G, Booth L, Smith AB, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol. 2004;22:714-724.
5. Detmar SB, Muller MJ, Schornagel JH, et al. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA. 2002;288:3027-3034.
6. Sandborn WJ, Feagan BG, Hanauer SB, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-530.
7. Salaffi F, Stancati A, Silvestri CA, et al. Minimally clinically important changes in chronic musculoskeletal pain intensity measured on a numeric rating scale. Eur J Pain. 2004;8:283-291.
8. Samulak D, Michalska M, Gaca M, et al. Efficiency of postoperative pain management after gynecologic oncological surgeries with the use of morphine + acetaminophen + ketoprofen versus morphine + metamizol + ketoprofen. Eur J Gynaecol Oncol. 2001;32:168-170.
9. Van Seventer R, Serpell M, Bach FW, et al. Relationships between changes in pain severity and other patient-reported outcomes: an analysis in patients with posttraumatic peripheral neuropathic pain. Health Qual Life Outcomes. 2011;9:17.
10. Eckmann MS, Ramamurthy S, Griffin JG. Intravenous regional ketorolac and lidocaine in the treatment of complex regional pain syndrome of the lower extremity: a randomized, double-blinded, crossover study. Clin J Pain. 2011;27:203-206.
11. Simpson DM, Schifitto G, 1066 HIV Neuropathy Study Group, et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology. 2010;74:413-420.
12. Birnbaum J, Kip M, Spies CD, et al. The effect of stimulation versus nonstimulating catheters for continuous interscalene plexus blocks in short-term pain management. J Clin Anesth. 2007;19:434-439.
13. Funk W, Podmelle F, Guiol C, et al. Aesthetic satisfaction scoring- introducing an aesthetic numeric analogue scale (ANA-scale). J Craniomaxillofac Surg. 2011;40:439-442.
14. Gossec L, Paternotte S, Aanerud GJ, et al. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis. 2011;70:935-942.
15. Wig J, Chandrashekharappa KN, Yaddanapudi LN, et al. Effect of prophylactic odansetron on postoperative nausea and vomiting in patients on preoperative steroids undergoing craniotomy for supratnetorial tumors. J Neurosurg Anesthesiol. 2007;19:239-242.
16. Rabin R, De Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337-343.
17. Stermer E, Gaitini L, Yudashkin M, et al. Patient-controlled analgesia for conscious sedation during colonoscopy: a randomized controlled study. Gastrointest Endosc. 2000;5:278-281.
18. Spiegel B, Bolus R, Harris LA, et al. Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment Pharmacol Ther. 2009;30:1159-1170.
19. Livingston PM, Craike MJ, White VM, et al. A nurse-assisted screening and referral program for depression among survivors of colorectal cancer: feasibility study. Med J Aust. 2010;193:S83-S87.
20. Wilcox AR, Dragnev MCC, Darcey CJ, et al. A new tool to measure burden of Crohn's disease and its treatment: do patient and physician perceptions match? Inflamm Bowel Dis. 2010;16:645-650.
21. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:1-30.
22. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
23. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet. 1980;1:514.
24. Hlavaty T, Persoons P, Vermeire S, et al. Evaluation of short-term responsiveness and cutoff values for inflammatory bowel disease questionnaire in Crohn's Disease. Inflamm Bowel Dis. 2006;12:199-204.
25. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96:804-810.
26. Pallis AG, Mouzas IA, Vlachonikolis IG, et al. The inflammatory bowel disease questionnaire. A review of its national validation studies. Inflamm Bowel Dis. 2004;10:261-269.
27. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32.
28. Cohen J. A power primer. Psychol Bull. 1992;112:155-159.
29. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's relapse prevention trial study group. Gastroenterology. 1994;106:287-296.
30. Gray WN, Denson LA, Baldassano RN, et al. Disease activity, behavioral dysfunction, and health-related quality of life in adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1581-1586.
31. Banovic I, Gilibert D, Cosnes J. Crohn's disease and fatigue: constancy and co-variations of activity of the disease, depression, anxiety, and subjective quality of life. Psychol Health Med. 2010;15:394-405.
32. Kanwal F, Hays RD, Kilbourne AM, et al. Are physician-derived disease severity indices associated with health-related quality of life in patients with end-stage liver disease? Am J Gastroenterol. 2004;99:1726-1732.
33. Borstlap M, van de Laar M, Zant J, et al. Components of health: an analysis in rheumatoid arthritis using quality of life questionnaires and clinical and laboratory variables. Ann Rheum Dis. 1993;52:650-654.
34. Bardsley MJ, Astell S, McCallum A, et al. The performance of three measures of health status in an outpatient diabetes population. Diabet Med. 1993;10:619-626.
35. Beto JA, Bansal VK. Quality of life in treatment of hypertension: a metaanalysis of clinical trials. Am J Hypertens. 1992;5:125-133.
36. Laupacis A, Wong C, Churchill D. The use of generic and specific quality of life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group. Control Clin Trials. 1991;12:168S-179S.
37. Hjortswang H, Almer S, Strom M. The network: a strategy to describe the relationship between quality of life and disease activity. The case of inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1999;11:1099-1104.
38. Drossman DA, Leserman J, Li Z, et al. The rating form of IBD patient concerns: a new measure of health status. Psychosom Med. 1991;53:701-712.
39. Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflam Bowel Dis. 2007;13:1100-1105.
40. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140:1817-1826.
41. Cakal B, Akoz AG, Ustundag Y, et al. Red cell distribution width for assessment of activity of inflammatory bowel disease. Dig Dis Sci. 2009;54:842-847.
42. Rodgers AD, Cummins AG. CRP correlated with clinical score in ulcerative colitis but no in Crohn's disease. Dig Dis Sci. 2007;52:2063-2068.
43. Drossman DA, Patrick DL, Mitchell CM, et al. Health related quality of life in inflammatory bowel disease: functional status and patient worries and concerns. Dig Dis Sci. 1989;34:1379-1386.
44. Rubin DT, Siegel CA, Kane SV, et al. Impact of ulcerative colitis from patients' and physicians' perspectives: results from the UC: NORMAL survey. Inflamm Bowel Dis. 2009;15:581-588.
45. Sewitch MJ, Abrahamowicz M, Dobkin PL, et al. Measuring differences between patients' and physicians' health perceptions: the patient-physician discordance scale. J Behav Med. 2003;26:245-264.
46. Westwood N, Travis SPL. Review article: what do patients with inflammatory bowel disease want for their clinical management? Aliment Pharmacol Ther. 2008;27:1-8.
47. Wolfe BJ, Sirois FM. Beyond standard quality of life measures: the subjective experiences of living with inflammatory bowel disease. Qual Life Res. 2009;17:877-886.
48. Leeb BF, Sautner J, Leeb BA, et al. Lack of agreement between patients' and physicians' perspectives of rheumatoid arthritis disease activity changes. Scand J Rheumatol. 2006;35:441-446.
49. Rothwell PM, MacDowell Z, Wong CK, et al. Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. Br Med J. 1997;314:1580-1583.
50. Leong KP, Chong EY, Kong KO, et al. Discordant assessment of lupus activity between patients and their physicians: the Singapore experience. Lupus. 2010;19:100-106.
51. Slevin ML, Plant H, Lynch D, et al. Who should measure quality of life, the doctor or the patient? Br J Cancer. 1988;57:109-112.